Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

CLARIFICATION ANNOUNCEMENT (1) FINAL DIVIDEND; AND (2) CLOSURE OF REGISTER OF MEMBERS

INTRODUCTION

Reference is made to the Announcement in relation to the Annual Results for the Year Ended December 31, 2025 and the Proposed Change in Use of Unutilized Net Proceeds (the "**Annual Results Announcement**") dated March 30, 2026 of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**"). The Company would like to clarify that in the sections titled (1) "Final Dividend" and (2) "Closures of Register of Members – (ii) For entitlement of proposed Final Dividend" on pages 42 and 43 of the Annual Results Announcement, shall be amended as follows:

(1) "Final Dividend"

"Relevant resolution has been passed at a meeting of the Board held on March 30, 2026, and the Board proposed the distribution of a final dividend (the "**Final Dividend**") of RMB1.45 (tax inclusive) per ten ordinary shares of the Company for the year ended December 31, 2025.

If such profit distribution plan is reviewed and approved by shareholders of the Company at the 2025 annual general meeting to be held on Friday, May 22, 2026 (the "**2025 AGM**"), the Final Dividend will be distributed no later than Wednesday, July 22, 2026 to H shares shareholders whose names appear on the register of members of the Company's H shares on **Tuesday, June 2, 2026**. The Final Dividend is denominated and declared in Renminbi. The Final Dividend payable to the holders of the Company's H shares shall be paid in Hong Kong dollars. The amount of Hong Kong dollars payable shall be calculated on the basis of the average closing exchange rates for Hong Kong dollars as announced by the Foreign Exchange Trading Centre of the PRC one calendar week prior to the approval of the Final Dividend at the 2025 AGM."

(2) "Closures of Register of Members"

"ii. For entitlement of proposed Final Dividend

The register of members of the Company's H shares will be closed from **Friday, May 29, 2026 to Tuesday, June 2, 2026**, both days inclusive, during which period no transfer of H shares will be registered. In order to qualify for the proposed Final Dividend, all transfer of shares, accompanied by the relevant share certificates and transfer forms, must be lodged with the Company's H shares share registrar in Hong Kong, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on **Thursday, May 28, 2026**."

Save as stated above, all other information set out in the Annual Results Announcement remains unchanged.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, PRC
March 31, 2026

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Mr. Huang Peng, Mr. Yi Ming and Mr. Pu Hong.